An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AmerisourceBergen Provides Update on Capital Deployment
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
AmerisourceBergen Corporation (NYSE: ABC) has announced the resumption of share repurchases, leveraging excess free cash flow as part of its disciplined capital allocation strategy. The company is committed to retaining its investment grade credit ratings while planning to pay down $2 billion in debt by March 2023, ahead of the two-year timeline following the acquisition of Alliance Healthcare in June 2021.
Positive
Resuming share repurchases indicates confidence in financial health and cash flow.
On track to pay down $2 billion in debt by March 2023, ahead of schedule, demonstrating effective debt management.
Negative
None.
Resuming share repurchases with excess free cash flow
Remains committed to investment grade credit ratings
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--
AmerisourceBergen Corporation (NYSE: ABC) today announced that it is resuming share repurchases with excess free cash flow in accordance with the company’s disciplined approach to capital allocation.
The company remains fully committed to maintaining its investment grade credit ratings, which involves paying down $2 billion in debt within two years of the June 2021 acquisition of Alliance Healthcare. As noted during its most recent earnings call, the company is on track to achieve this debt paydown by March 2023, ahead of the two-year commitment.
The preceding descriptions of the Company’s approach to capital allocation constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, AmerisourceBergen undertakes no obligation to publicly update forward-looking statements. Investors should read the important risk factors described in AmerisourceBergen’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission.
About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com.
